Büscher K H, Cullmann W, Dick W, Stieglitz M
Chemotherapy. 1987;33(1):40-51. doi: 10.1159/000238474.
The frequency of selection of resistant variants by 10 different broad-spectrum beta-lactam derivatives was evaluated for 10 clinical Enterobacter cloacae isolates. With respect to most penams or cephems, resistant variants could be selected up to 8- or 32-fold the MIC, respectively. However, with cefpirome as the selecting agent resistant variants were obtained only at twice the MIC, whereas resistant variants were barely detectable with temocillin and not detectable in any case with imipenem. The variants exhibited cross-resistance between penams and cephems including aztreonam, but not to temocillin and imipenem regardless of the beta-lactamase amount produced. Enzyme production of the variants ranged from 0.2 U to 19.0 U beta-lactamase/mg protein of the cell-free supernatants. Moreover, analysis of the outer membrane protein composition did not reveal marked alterations between wild strains and the corresponding variants. It is evident that 'overproduction of the chromosomal beta-lactamase' cannot explain entirely phenotypic resistance to broad-spectrum beta-lactam compounds, but a lack of porin production, i.e., major outer membrane proteins, cannot provide an explanation for the above findings.
对10株临床分离的阴沟肠杆菌,评估了10种不同的广谱β-内酰胺衍生物选择耐药变异株的频率。对于大多数青霉烯类或头孢菌素类药物,耐药变异株的选择倍数分别可达最低抑菌浓度(MIC)的8倍或32倍。然而,以头孢匹罗作为选择剂时,仅在MIC的2倍时获得耐药变异株,而替莫西林几乎检测不到耐药变异株,亚胺培南在任何情况下均未检测到耐药变异株。这些变异株在青霉烯类和头孢菌素类(包括氨曲南)之间表现出交叉耐药性,但无论β-内酰胺酶产生量如何,对替莫西林和亚胺培南均无交叉耐药性。变异株的酶产量范围为无细胞上清液中每毫克蛋白质0.2 U至19.0 Uβ-内酰胺酶。此外,外膜蛋白组成分析未显示野生菌株与相应变异株之间有明显变化。显然,“染色体β-内酰胺酶的过量产生”不能完全解释对广谱β-内酰胺化合物的表型耐药性,但孔蛋白(即主要外膜蛋白)的缺乏不能解释上述发现。